The skin disorder known as nephrogenic systemic fibrosis, NSF, can affect people of all ages. This condition causes the skin on a person's body to thicken in areas including hands and feet. 

People with kidney disorders are more susceptible to developing this disease. The contrast agent, gadolinium, is used in MRI scans and has been linked to the development of this disorder in patients suffering from kidney problems. The length of time that a person has been dealing with kidney problems does not matter in regards to this disorder.

Children with kidney problems can begin to show signs of this condition just like middle-aged adults.

If you or someone you know has NSF, you may be entitled to compensation. Please contact the gadolinium lawyers of Williams Kherkher by calling 800-761-3187 today. 

Nephrogenic Systemic Fibrosis is a condition that can result from the contact with Gadolinium in patients with kidney problems. This syndrome is serious and life-changing.

There are several symptoms associated with NSF including: 

• Hardening of the skin 
• Dry,irritated areas of the skin 
• Patches of skin that become red or dark
• Joints becoming rigid and inflexible mainly in the hands and feet

NSF currently has no cure and in some cases can even result in death.

If you have developed NSF and have any of these symptoms as a result of gadolinium, please contact the NSF lawyers of Williams Kherkher by calling 800-761-3187 today.

Over the past several years, researchers have found a correlation between the development of Nephrogenic Systemic Fibrosis and the increasing use of gadolinium-based MRI contrast agents.

Gadolinium, an element of the lanthanide series, is the chief component of virtually all contrast agents administered for magnetic resonance imaging. It has been linked to the development of Nephrogenic Systemic Fibrosis, formerly known as Nephrogenic Fibrosing Dermopathy. Nephrogenic Systemic Fibrosis is a systemic disorder with its most visible effects on the skin. NSF patients experience swelling and tightening of the skin.

The skin changes may begin as reddened or darkened patches or papules. Patients may experience burning, itching, or severe sharp pains in areas of involvement. 

If you or someone you love has been diagnosed with Nephrogenic Systemic Fibrosis, or NSF, and a gadolinium-based contrast agent used in an MRI scan may be to blame, you may be entitled to compensation for your injuries and suffering. Know your rights and a options, and be sure you are in contact with an experience legal team. If you need advice, contact the gadolinium attorneys of Williams Kherkher at 800-761-3187 today.

The American College of Radiology has advised doctors to avoid using three specific types of common gadolinium-based contrast agents when administering MRIs. 

According to an advisory from the ACR, three common contrast agents -  gadodiamide or Omniscan by GE Healthcare, gadopentetate dimeglumine or Magnevist by Bayer Healthcare Pharmaceuticals, and Gadoversetamide by OptiMARK by Covidien - are linked with a greater number of nephrogenic systemic fibrosis cases. As of December 2009, NSF disease has been documented in 382 patients who received gadodiamide, out of 13 million doses; 195 patients who received gadopentetate dimeglumine, out of 23 million doses; and in 35 patients who received gadoversetamide, out of 4.7 million doses, according to the United States Food and Drug Administration. 

Nephrogenic systemic fibrosis is an extremely rare and incurable condition. Richard Cohan, MD, professor of abdominal radiology at the University of Michigan said that of all the patients who receive gadolinium with an MRI "more than 90 percent... will not develop NSF."

If you or someone you love has been diagnosed with Nephrogenic Systemic Fibrosis, or NSF, and a gadolinium-based contrast agent used in an MRI scan may be to blame, you may be entitled to compensation for your injuries and suffering. Know your rights and a options, and be sure you are in contact with an experience legal team. If you need advice, contact the gadolinium attorneys of Williams Kherkher at 800-761-3187 today.

Contrast agents, also known as contrast media, are compounds used to increase visibility and clarity in medical scans. They allow physicians to reveal diseases and other maladies without using invasive procedures that, without this increased clarity, would otherwise be undetectable to basic scanning methods.

Major producers of contrast agents include GE Healthcare, Bayer Pharmaceuticals, and Bracco Imaging. They are expected to grow a currently $5.4 billion industry in 2008 to a $7.9 billion industry in 2015. Smaller pharmaceutical producers currently involved in developing the generic market for contrast agents are also increasing the profitability of the overall market. Patents for X-ray and MRI-related contrast agents are due to expire within a few years, opening the possibility for generic market growth.

In the case of contrast agents, different scans require different products. Ultrasound contrast agents are generally regarded as less dangerous, using gas microbubble technologies to clarify their resolution. On the other hand, gadolinium-based agents used in X-ray and MRI scans has been linked to serious complications. These agents have been found to be related to the development of nephrogenic systemic fibrosis, or NSF, especially in patients with kidney problems.

If you have developed NSF because of gadolinium-based agents, you may be eligible for compensation. Contact the gadolinium attorneys of Williams Kherkher by calling 800-761-3187.